FDA Adverse Event Injury Summary report: N

GORE DUALMESH BIOMATERIAL

MDR report key: 2202333 · Received August 5, 2011

Report

Report Number
3003910212-2011-00015
Event Type
Injury
Date Received
August 5, 2011
Date of Event
February 22, 2011
Report Date
August 4, 2011
Manufacturer
W.L. GORE & ASSOCIATES
Product Code
FTL
PMA / PMN Number
K992189
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NY, US
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

METHOD: THE DEVICE WAS NOT RETURNED AND THE LOT NUMBER IS UNAVAILABLE, THEREFORE, A DIRECT PRODUCT ANALYSIS AND REVIEW OF MANUFACTURING RECORDS WAS NOT CONDUCTED. THE POTENTIAL FOR SUCH EVENTS IS ADDRESSED IN THE DEVICE'S INSTRUCTIONS-FOR-USE WHICH STATES, "POSSIBLE ADVERSE REACTIONS WITH THE USE OF ANY TISSUE DEFICIENCY PROSTHESIS MAY INCLUDE, BUT ARE NOT LIMITED TO, CONTAMINATION, INFECTION, INFLAMMATION, ADHESION, FISTULA FORMATION, SEROMA FORMATION, HEMATOMA AND RECURRENCE." ALL INFO HAS BEEN MADE AVAILABLE FOR TRACKING AND TRENDING.

Description of Event or Problem · 1

IT WAS REPORTED TO GORE THAT A PT UNDERWENT AN EXPLORATORY LAPAROTOMY FOR PERSISTENT HIGH GRADE BOWEL OBSTRUCTION. LYSIS OF ADHESIONS AND A SMALL BOWEL RESECTION WAS PERFORMED AFTER ENTERING THE ABDOMEN THROUGH WELL INCORPORATED GORE DUALMESH BIOMATERIAL. GORE DUALMESH BIOMATERIAL HAD BEEN IMPLANTED EIGHT YEARS PRIOR FOR VENTRAL HERNIA REPAIR. NINE DAYS POST OPERATIVE; THE PT PRESENTED IN SEPTIC SHOCK. THERE WAS FECULENT WOUND DRAINAGE AND CT REVEALED EXPOSED GORE DUALMESH BIOMATERIAL AT THE BASE OF THE MIDLINE INCISION. THE PT WAS RESUSCITATED AND A WOUND VAC WAS APPLIED. SEVERAL DAYS LATER, THE MESH WAS REMOVED AND THE FASCIA WAS REAPPROXIMATED ALONG THE MIDLINE AND AN ONLAY REPAIR WAS PERFORMED. IT WAS REPORTED THAT THE PT'S RECOVERY WAS UNREMARKABLE AND THE INCISION HEALED WITHOUT COMPLICATION ONE MONTH AFTER SURGERY.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 GORE DUALMESH BIOMATERIAL FTL / MESH, SURGICAL, POLYMERIC FTL W.L. GORE & ASSOCIATES WLG101

Patients

Seq Age Sex Outcome Treatment
1 78 YR Required Intervention